– USA FL – Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system, today announced the appointment of Fabiana Fedeli to its Board as an independent director.
“Fabiana is a renowned global capital markets expert, and we are delighted to add her to the Board. Fabiana’s extensive global business and economic expertise adds important diversity to the Board and will be invaluable to us as we approach potential commercialization of REL-1017. On behalf of the entire Board, we look forward to working closely with Fabiana to further enhance long-term shareholder value,” said Board Chairman, Chuck Casamento.
About Fabiana Fedeli
Fabiana Fedeli has extensive knowledge of international capital markets, sustainability, governance, and corporate strategy. In her current role at M&G Investments, which Ms. Fedeli joined in 2021, she leads a team of over 100 investment professionals with assets deployed across the globe. She is responsible for teams managing assets in the UK, US, Singapore, Hong Kong, and France. Before joining M&G Investments, Ms. Fedeli served as Global Head of Fundamental Equities, Managing Director, at Robeco Asset Management, from 2013-2021. In this role, she led Robeco’s Fundamental Equities investments, with over 70 direct and indirect reports based in Rotterdam, Zurich, Hong Kong, and Shanghai, for total assets under management of $47 billion. Earlier in Ms. Fedeli’s career, she held senior portfolio management and research positions at multiple leading institutional investment firms and investment banks, including Pioneer Investment Management, Occam Asset Management, Indus Capital Partners, Lehman Brothers, and ING Barings Corp.
“I am thrilled to be joining Relmada’s Board at this exciting time in the Company’s corporate evolution,” said Fabiana Fedeli. “I firmly believe that Relmada has many potentially value-creating opportunities ahead, and am eager to work with the rest of the Board and the management team to best leverage these exciting prospects.”
Ms. Fedeli holds advisory and board positions and regularly speaks at industry events on asset allocation, governance, and sustainability. Fabiana is a member of the Investment Committee of The Investment Association, a trade body representing Investment Managers in the UK that collectively manage over US$12 trillion in assets. She is also a member of the Investment Committee of UK-based The Open University, and a non-executive director on the Board of M&G Investments South Africa. In 2022, she was named by Financial News as one of the 100 Most Influential Women in Finance. She is regularly published in print and interviewed on TV and radio. Ms. Fedeli holds a Master of Economics from Hitosubashi University in Tokyo, Japan, and a Bachelor’s in Economics from Bocconi University in Milan, Italy. She also received a Certificate in Financial Asset Management and Engineering from the University of Lausanne, Swiss France Institute, in Lausanne, Switzerland.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system, with a focus on major depressive disorder. Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity and novel NMDA receptor channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 has entered late-stage development as an adjunctive treatment for MDD in adults. In addition, Relmada is advancing a clinical-stage program in neurodegenerative diseases based on psilocybin and select derivative molecules.
For more information: https://www.relmada.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
